The latest announcement is out from Context Therapeutics (CNTX).
Context Therapeutics Inc. has initiated a private placement deal to raise approximately $100 million by selling common stock and pre-funded warrants, with the proceeds aimed at funding their clinical-stage product research and general corporate needs. The deal includes certain conditions, such as lock-up agreements for company executives and the filing of a registration statement with the SEC. Furthermore, the FDA’s approval of the company’s IND application for CTIM-76 marks a significant step forward, enabling the commencement of Phase 1 clinical trials, with the private placement expected to extend the company’s financial runway well into 2028.
For an in-depth examination of CNTX stock, go to TipRanks’ Stock Analysis page.
